Puma Biotechnology Experiences Inducement Awards Underneath Nasdaq Itemizing Rule 5635(c)(4)

LOS ANGELES, September 02, 2022–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical firm, introduced that on September 1, 2022, the Compensation Committee of Puma’s Board of Administrators authorised the grant of inducement restricted inventory unit awards overlaying 18,750 shares of Puma frequent inventory to 2 new non-executive staff.

The awards have been granted below Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and supplies for the granting of fairness awards to new staff of Puma. The restricted inventory unit awards vest over a three-year interval, with one-third of the shares underlying every award vesting on the primary anniversary of the award’s vesting graduation date, September 1, 2022, and one-sixth of the shares underlying every award vesting on every six-month anniversary of the vesting graduation date thereafter, topic to continued service. The awards have been granted as an inducement materials to the brand new staff coming into into employment with Puma, in accordance with Nasdaq Itemizing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical firm with a give attention to the event and commercialization of progressive merchandise to boost most cancers care. Puma in-licenses the worldwide improvement and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was authorised by the U.S. Meals and Drug Administration in 2017 for the prolonged adjuvant remedy of grownup sufferers with early stage HER2-overexpressed/amplified breast most cancers, following adjuvant trastuzumab-based remedy, and is marketed in the USA as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was additionally authorised by the FDA together with capecitabine for the remedy of grownup sufferers with superior or metastatic HER2-positive breast most cancers who’ve acquired two or extra prior anti-HER2-based regimens within the metastatic setting. NERLYNX was granted advertising and marketing authorization by the European Fee in 2018 for the prolonged adjuvant remedy of grownup sufferers with early stage hormone receptor-positive HER2-overexpressed/amplified breast most cancers and who’re lower than one 12 months from completion of prior adjuvant trastuzumab-based remedy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20220902005318/en/

Contacts

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com